Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences (LOBEF) appointed Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 20, 2026, to oversee clinical development. He most recently held the same role at clinical research organization Linical. The company is preparing a U.S. Investigational New Drug application for L-130, its psilocin-based candidate for generalized anxiety disorder, and advancing S-100, an oral lipid formulation for sickle cell disease, toward Phase 3 development.
Lobe also engaged Independent Trading Group for market-making services commencing October 19, 2026, at C$6,000 per month plus applicable taxes. The agreement renews monthly after an initial one-month term unless either party gives 30 days' termination notice. No shares or options will be issued as compensation.
Lobe Sciences (LOBEF) appointed life sciences investment banker Annette Grimaldi to its Board of Directors, adding a director with financing experience.
Grimaldi has 35 years of experience advising executives and boards on public and private financings, mergers and acquisitions, and other transactions. From 2009 to 2024, she established and led BMO Capital Markets' life sciences investment banking practice. She previously led the life sciences investment banking practice at Jefferies and held roles at SG Cowen and Goldman Sachs.
In connection with the appointment, Grimaldi received 4,000,000 restricted share units under the company's equity incentive plan and applicable regulatory requirements.
Lobe Sciences (LOBEF) plans capital markets initiatives involving independent market-making services, expanded investor communications and an additional director with U.S. capital markets experience.
The company intends these initiatives to broaden awareness and support trading liquidity. No market-making or communications provider has been selected, and engagement terms remain unagreed. Investor relations engagements require CSE acceptance. Lobe anticipates submitting a U.S. Investigational New Drug application, seeking permission for clinical testing of L-130, in the first quarter of 2027. Separately, it expects Phase 3 development of S-100 for sickle cell disease to begin in mid-2027.
Lobe Sciences (LOBEF) will present new clinical and preclinical data on its lead CNS candidate Conjugated Psilocin (L-130) at the 9th Neuropsychiatric Drug Development Summit in Boston, held September 15-17, 2026.
Chairman and CEO Dr. Frederick D. Sancilio will speak on September 16 at 11:00 a.m. ET in the summit's preclinical and translational track, outlining Phase 1a first-in-human results in ten subjects. The presentation will cover oral bioavailability, dose consistency, and an absence of hallucinogenic effects at low doses, supporting L-130’s positioning for daily outpatient dosing rather than supervised in-clinic psychedelic administration.
L-130 is described as a patented salt of psilocin and a new chemical entity initially developed for cluster headache, with co-development programs in PTSD, substance use disorder, generalized anxiety disorder and other neuropsychiatric conditions. Lobe is also advancing S-100 for sickle cell disease, with Phase 3 development anticipated to start in mid-2027.
Lobe Sciences (LOBEF) will attend the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, at the Sheraton Center Toronto Hotel.
Chief Financial Officer Dr. David Kideckel will represent Lobe as a Featured Company and hold one-on-one meetings with interested investors and capital markets professionals. The company highlights its lead CNS asset L-130 (Conjugated Psilocin®), a patented compound designed to deliver predictable psilocin exposure and initially developed for cluster headache, with additional co-development programs in PTSD, substance use disorder, generalized anxiety disorder and other neuropsychiatric conditions. Lobe is also advancing S-100 for sickle cell disease, with Phase 3 clinical development anticipated to begin in mid-2027.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) has closed the second tranche of its non-brokered private placement of common shares at $0.085 per share. The second tranche comprised 705,882 shares for gross proceeds of $60,000, following a first tranche of 24,705,880 shares for $2,100,000 closed on August 19, 2026.
In total, the company issued 25,411,762 shares for aggregate gross proceeds of $2,160,000. According to Lobe, proceeds will fund working capital, general corporate purposes, and advancement of its S-100 drug candidate for sickle cell disease through subsidiary Applied Lipid Technologies, which has already secured the required active pharmaceutical ingredient.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) has upsized its previously announced non-brokered private placement of common shares at $0.085 per share. The company closed a first tranche on August 19, 2026, issuing 24,705,880 shares for gross proceeds of $2,100,000. It intends to close a second tranche of 705,882 shares for approximately $60,000, bringing the total to 25,411,762 shares and $2,160,000 in gross proceeds, subject to Canadian Securities Exchange approval. Proceeds are earmarked for working capital, general corporate purposes, and advancing Lobe’s S-100 drug candidate for sickle cell disease, including funding subsidiary Applied Lipid Technologies’ work toward human clinical trials using already procured active pharmaceutical ingredient.
Lobe Sciences (OTCQB: LOBEF) announced the appointment of Dr. David Kideckel, PhD, MBA as Chief Financial Officer, effective September 1, 2026, subject to acceptance by the Canadian Securities Exchange. Current CFO Mirza Rahimani will transition to Vice President of Finance on the same date, maintaining continuity in accounting, reporting, compliance and financial operations.
According to Lobe, Dr. Kideckel brings nearly two decades of experience spanning life sciences, capital markets and corporate advisory roles, including senior positions at a large North American private investment bank, Johnson & Johnson and Alexion Pharmaceuticals. The company highlights this leadership change as support for advancing its clinical-stage pipeline, including L-130 for chronic cluster headache and S-100 for sickle cell disease.
Lobe Sciences (OTCQB: LOBEF) closed its previously announced non-brokered private placement, issuing 24,705,880 common shares at $0.085 per share for gross proceeds of approximately $2.1 million. All securities are subject to a four-month hold period under Canadian securities laws.
According to the company, net proceeds will fund working capital, general corporate purposes, and advancement of its S-100 drug candidate for sickle cell disease. A portion will be allocated to wholly owned subsidiary Applied Lipid Technologies to progress S-100 toward human clinical trials, supported by procurement of the required active pharmaceutical ingredient.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) reported unaudited Q3 2026 results for the period ended May 31, 2026. Cash was $1.51 million with short-term investments of $3.70 million, and net working capital totaled $3.20 million.
R&D expenses for the nine months were $2.45 million, up from $0.30 million a year earlier, tied to Cynaptec’s L-130 and Applied Lipid Technologies’ S-100 programs. Cash used in operating activities for the nine months was $3.35 million, versus $1.02 million in the prior-year period. Net loss for the quarter was $4.84 million, compared with $2.64 million last year.
Directors and officers settled $1.37 million of accrued fees for 12.48 million shares at $0.11, and the company closed a $0.95 million non-brokered private placement at $0.065 per share. A further $2.10 million private placement at $0.085 per share is anticipated to close around August 19, 2026, subject to regulatory approvals.